Fig. 4.

Guideline for monitoring LVEF for Class I and Class II agents adapted from Plana JC et. al. J Am Soc Echocardiogr 2014;27:911–39.

** CMR should be considered in high risk patients for cardiotoxicity when echo quality is limited or EF is uncertain. A non-contrast abbreviated protocol for EF assessment can be used at baseline and follow-up at intervals directed above. CMR with gadolinium can be used when there are concerns for myocarditis or scar imaging is necessary.